Clinical Trials Sponsored by Prosensa Therapeutics

Total 6337 results

ProQR Therapeutics

Active, not recruiting

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) (ILLUMINATE)

Eye Diseases | Neurologic Manifestations | Eye Diseases, Hereditary | Sensation Disorders | Vision Disorders | Blindness | Leber Congenital Amaurosis | Leber Congenital Amaurosis 10 | Retinal Disease | Eye Disorders Congenital

United States, Belgium, Brazil, Canada, France, Germany, Italy, Netherlands, United Kingdom
Aligos Therapeutics

Terminated

A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Chronic Hepatitis B

Korea, Republic of, China, Hong Kong, United Kingdom, New Zealand, Moldova, Republic of
Cartesian Therapeutics

Completed

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

Multiple Myeloma

United States
Allarity Therapeutics

Completed

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (LiPlaCis)

Phase 1: Advanced or Refractory Solid Tumours | Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer

Denmark
Heron Therapeutics

Completed

Dose-Escalation Study of HTX-034 Following Bunionectomy

Bunions

United States
Sage Therapeutics

Completed

A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Healthy Volunteer

United States
Sage Therapeutics

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B

Huntington Disease

United States
Sage Therapeutics

Completed

A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)

Postpartum Depression

United States
Sage Therapeutics

Completed

A Study With SAGE-547 for Super-Refractory Status Epilepticus

Super-Refractory Status Epilepticus

United States, Austria, Canada, Denmark, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Serbia, Spain, Sweden, United Kingdom
Sage Therapeutics

Completed

Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression

Postpartum Depression

United States
Amicus Therapeutics

Completed

Gene Therapy for Children With Variant Late Infantile Neuronal Ceroid Lipofuscinosis 6 (vLINCL6) Disease

Variant Late-Infantile Neuronal Ceroid Lipofuscinosis

United States
Celldex Therapeutics

Completed

A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

Healthy Subjects

United States
Sage Therapeutics

Completed

Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants

Healthy Volunteer

United States
Halozyme Therapeutics

Completed

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

Dermatitis, Allergic Contact

United States
CytomX Therapeutics

Terminated

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Solid Tumor | Unresectable or Metastatic Melanoma

Korea, Republic of, United States, Netherlands, Spain, Australia
Fate Therapeutics

Terminated

The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.

Hematologic Malignancies

United States
Fate Therapeutics

Completed

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | HER2 Positive Gastric Cancer | EGFR Positive Solid Tumor

United States
Fulcrum Therapeutics

Completed

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

Healthy Adult Subjects

United States
Blade Therapeutics

Completed

Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations

Relative Bioavailability

Australia
Heron Therapeutics

Completed

Phase 2B Upper Extremity Nerve Block Study

Postoperative Pain

United States
Halozyme Therapeutics

Completed

Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer

Bladder Cancer

United States
TR Therapeutics

Completed

Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation

Wounds

United States
Heron Therapeutics

Completed

Bunionectomy Study for Postoperative Analgesia (EPOCH 1)

Postoperative Pain

United States
Heron Therapeutics

Completed

Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)

Postoperative Pain

United States, Belgium
Heron Therapeutics

Completed

Phase 2 Herniorrhaphy Study for Opioid Elimination

Postoperative Pain

United States
Causeway Therapeutics

Completed

Safety, Tolerability, and Pharmacokinetics of Single Dose TenoMiR as a Treatment for Tennis Elbow

Tennis Elbow

United Kingdom
Corcept Therapeutics

Completed

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

Healthy

United States
UNION therapeutics

Completed

Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers

Covid19

Denmark
Phoenicis Therapeutics

Terminated

A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

Epidermolysis Bullosa Dystrophica, Recessive | Epidermolysis Bullosa Dystrophica, Dominant

United States, Spain, France
Allergy Therapeutics

Withdrawn

Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)

Type I Hypersensitivity

Canada
Cadent Therapeutics

Completed

A Clinical Study to Evaluate CAD-1883 in Essential Tremor

Essential Tremor

United States
Nektar Therapeutics

Completed

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Colorectal Cancer

United States, Belgium, Germany, India, Spain, United Kingdom
Nektar Therapeutics

Terminated

A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.

Moderate to Severe Chronic Pain

United States
AKARI Therapeutics

Completed

rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects

Bullous Pemphigoid (BP)

Germany, Netherlands
Nektar Therapeutics

Completed

The BEACON Study (Breast Cancer Outcomes With NKTR-102) (BEACON)

Metastatic Breast Cancer | Locally Recurrent Breast Cancer

United States, Spain, Korea, Republic of, Canada, United Kingdom, Germany, France, Netherlands, Belgium, Italy, Russian Federation
vTv Therapeutics

Terminated

2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)

Alzheimer's Disease

United States, Canada
Bioniz Therapeutics

Completed

A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL

LGL Leukemia | CTCL

United States
Intrinsic Therapeutics

Withdrawn

Incidence of Large Annular Defects in Primary Lumbar Discectomy Patients (USLSI)

Lumbar Disc Herniation | Anular Tear of Lumbar Disc | Nucleus Pulp Hernia;Lumbosac

United States
Allergy Therapeutics

Completed

Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen

Type I Hypersensitivity

Canada
CytomX Therapeutics

Withdrawn

PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors

Solid Tumor, Adult

United States
Symbiomix Therapeutics

Completed

Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219

Bacterial Vaginosis

United States
Akebia Therapeutics

Completed

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis Dependent Chronic Kidney Disease

Japan
Acorda Therapeutics

Completed

A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial (TQT)

Spasticity

United States
Sangamo Therapeutics

Completed

Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART

Human Immunodeficiency Virus (HIV)

United States
Blade Therapeutics

Withdrawn

Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF

Idiopathic Pulmonary Fibrosis

United Kingdom
Cristal Therapeutics

Completed

Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer (CINOVA)

Cancer | Ovarian Cancer

Netherlands, Belgium, United Kingdom
Amicus Therapeutics

Completed

Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease

Fabry Disease

United States, Austria, United Kingdom, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Egypt, France, Italy, Japan, Spain, Turkey
PTC Therapeutics

Completed

Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada

Duchenne Muscular Dystrophy | Becker Muscular Dystrophy | Dystrophinopathy

United Kingdom, Canada, Germany, Spain, Sweden, Italy, Australia, Belgium, France, Israel
Arthrosi Therapeutics

Completed

The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males

Healthy Volunteers

Australia
Symbiomix Therapeutics

Completed

A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis

Bacterial Vaginosis

United States

3

Subscribe